Clinical Guidelines Portal

Home > Guidelines > Perinatal Guidelines > Appendix B: Acronyms
Text Size
Search

Guideline Search

Type your search term(s) in the text box. Users can only search one guideline at a time. To search for an exact phrase, use quotation marks (i.e. "what to start"). To narrow your search, add additional relevant terms. If you are not finding what you need, try searching similar terms (i.e. perinatal OR pregnancy) to broaden your search.

Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States

Appendix B: Acronyms

(Last updated:9/14/2011)

Printer-Friendly Files

3TC lamivudine

ABC abacavir
ALT alanine aminotransferase
AOR adjusted odds ratio
AP antepartum
APV amprenavir
ART antiretroviral therapy/treatment
ARV antiretroviral
AST aspartate aminotransferase
ATV atazanavir
ATV/r atazanavir/ritonavir
AUC area under the curve

BID twice daily

CBC complete blood count
CDC Centers for Disease Control and Prevention
CI confidence interval
Cmax maximum plasma concentration
Cmin minimum plasma concentration
CMV cytomegalovirus
CNS central nervous system
CVS chorionic villus sampling
CYP cytochrome P
CYP3A4 cytochrome P450 3A4

d4T stavudine
ddC zalcitibine
ddI didanosine
DLV delavirdine
DMPA depot medroxyprogesterone acetate
DRV darunavir
DRV/r darunavir/ritonavir
DSMB Data and Safety Monitoring Board

EFV efavirenz
EKG electrocardiogram
EMS ethyl methane sulfonate
ETR etravirine

FDA Food and Drug Administration
FPV fosamprenavir
FPV/r fosamprenavir/ritonavir
FTC emtricitibine

HAV   hepatitis A virus
HBIG hepatitis B immune globulin
HBV hepatitis B virus
HCV hepatitis C virus
HELLP hemolysis, elevated liver enzymes, and low platelets (syndrome)
HHS Department of Health and Human Services
HRSA Health Resources and Services Administration
HSV herpes simplex virus

IC50 50% inhibitory concentration
IDV indinavir
IgG immunoglobulin G
IMPAACT International Maternal Pediatric Adolescent AIDS Clinical Trials Group
IP intrapartum
IQR interquartile range 
IRIS immune reconstitution inflammatory syndrome
IUD intrauterine device

LPV/r lopinavir/ritonavir

MAC Mycobacterium avium complex
MIRIAD Mother-Infant Rapid Intervention at Delivery (study)
mtDNA mitochondrial DNA
MVC maraviroc

NAAT nucleic acid amplification testing
NFV nelfinavir
NIH National Institutes of Health
NNRTI non-nucleoside reverse transcriptase inhibitor
NRTI nucleoside reverse transcriptase inhibitor
NtRTI nucleotide reverse transcriptase inhibitor
NVP nevirapine

OARAC Office of AIDS Research Advisory Council
OC oral contraceptive
OCTANE Optimal Combination Therapy After Nevirapine Exposure (study)
OI opportunistic infection
OR odds ratio

PBMC peripheral blood mononuclear cell
PCP Pneumocystis jirovecii pneumonia
PCR polymerase chain reaction
PHACS Pediatric HIV/AIDS Cohort Study
PI protease inhibitor
PK pharmacokinetic
po orally
PP postpartum
PPI proton pump inhibitor

RAL Raltegravir
RDS respiratory distress syndrome
RPV rilpivirine
RR relative risk
RTV ritonavir

sd single-dose

SQV saquinavir
SQV/r saquinavir/ritonavir
STI sexually transmitted infection
SWEN Six Week Extended-Dose Nevirapine (study)

T-20 enfuvirtide
TAM thymidine-associated mutation
TDF tenofovir disoproxil fumarate
TB tuberculosis
TID three times daily
TMP-SMX trimethoprim-sulfamethoxazole
TPV tipranavir
 TPV/r tipranavir/ritonavir

UGT uridine diphosphate glucuronosyltransferase

WHO World Health Organization
WITS Women and Infants Transmission Study

ZDV zidovudine